Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polystictus glycopeptide is an immunomodulatory natural product extract derived from the deep fermentation mycelium of the fungus *Polystictus versicolor* (also known as *Coriolus versicolor* or Yunzhi). It is a complex glycopeptide composed of polysaccharide-peptide polymers. The drug functions primarily as an immunostimulant, enhancing the activity of macrophages, T-lymphocytes, and natural killer (NK) cells, while also inducing the production of various cytokines. In China, it is manufactured by companies such as Shenghua Pharmaceutical Technology and is approved for the treatment of chronic hepatitis B, as an adjuvant therapy for liver cancer to improve immune function during chemotherapy or radiotherapy, and for addressing immune deficiency conditions in elderly patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polystictus glycopeptide.